Tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for LA-PDAC #ASCO25 🔎PANOVA-3 phs 3 👉mPFS 10.6 vs9.3 mo 👉mDFS 13.9 vs 11.5 👉mOS 16.2 vs 14.2 mo 👉better Qol & pain free survival, but skin tox 🧐Positive, but interesting to see whether & how it will

Neoadjuvant Gem/Cis vs radical liver resection followed by adjuvant therapy in BTC #ASCO25 🔎 phase III AIO/CALGP/ACO-GAIN-Trial. 👉RO 83 vs 40% 👉mEFS 14 vs 4 mo 👉mOS 27 vs 14 mo 🧐 Strong signal, but unfortunately stopped premature. 🧐 Supports neaadjuvant strategies in BTC

CLDN18.2 expression and efficacy in PDAC: phase I dose expansion cohort with IBI343. #ASCO25 🔎Phs-1: >60% vs <60% 👉ORR 22 vs 0% 👉mPFS 5.5 vs 1.4mo 👉mOS 9.1 vs 6.2 🧐 Looks really promising in >60%, manageable AEs ESMO - Eur. Oncology

Have you or a loved one been treated for liver cancer with nivolumab + ipilimumab? We want to hear from you! Your input will help guide this treatments funding by the Canada healthcare system. surveymonkey.com/r/PMLBCKX Hashtags: #CCRAN #LiverCancer #Immunotherapy #Cancer

So happy to be asked to speak at this amazing meeting! Comprehensive genomic profiling is going to be key for identifying treatment options for patients, treatments that won’t work and also how to screen patients down the road!

From Grainne O'Kane Notta Lab & colleagues in Nature Communications : Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial nature.com/articles/s4146… Another study showing the association between basal subtype & major KRAS allelic imbalance.

🔥Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer🔥 👉great news, another 🇪🇺 approval in BTC 🧐Don't forget IHC Her2 testing in BTC! ESMO - Eur. Oncology EASL Education ILCA

🚨 GI Cancer Mortality to Double by 2050📊 ESMO GI 2025 shows sharp rise in deaths due to: 🔹 Colorectal: +103% 🔹 Pancreatic: +100% 🔹 Esophageal: +86% 🔹 Liver: +81% 🌍 Biggest increases in Asia & Africa 💡 Call to action: Early detection, access, equity. Time for GI oncologist

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25%

Looking forward to this!

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx nature.com/articles/s4146…

Positive phase 2 data of #olaparib in patients with advanced biliary tract cancer #BTC #CCA with aberrant #HRR mutations presented today at #ESMOGI25 ESMO - Eur. Oncology #ESMOAmbassadors

Nice slide to show evolution of various gudilelines over the years for Neoadjuvant and Adjuvant therapy in BTC ( including GB ) From educational session by Dr Gonzalo ESMO - Eur. Oncology #ESMOGI2025

What is beyond IO and TKI in HCC ? Bispecific and Anti TIGIT. Nice slides to show current data for both. ESMO - Eur. Oncology #esmogi2025

A phase III randomized study of first-line NUC-1031/cisplatin vs GemCis in advanced biliary tract cancer Journal of Hepatology doi.org/10.1016/j.jhep… 👉mPFS 4.9 vs 6.4 mo 👉mOS 9.2 vs 12.6 mo 🧐Interesting concept, but detrimental outcome ESMO - Eur. Oncology EASL Education Cholangiocarcinoma Foundation ILCA

🤨5,000 patients later Roche scraps its TIGIT 👇oncologypipeline.com/apexonco/5000-…

Proud and honored to be part of The Lancet Commission on #livercancer #HCC led by Stephen L. Chan. Humanitas University Humanitas Milano 3 Out of 5 Liver Cancer Cases Are Preventable, Study Finds nytimes.com/2025/07/28/wel… via @NYTimes

🧠 Cancer responds. Surgeons wait. Patients lose. In our new Converse Study (n=2,379 HCC patients), 16% responded well enough to be potentially cured after Atezolizumab+Bevacizumab. But only 3% actually received curative treatment. We call this the under-conversion gap:

Another week on the inpatient oncology service and this time had MULTIPLE folks come in in critical condition because they went to a quack and tried to treat their once curable cancer with supplements, tinctures, extreme diets or just ivermectin and fenbendazole. Cancer patients

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced HCC or gastric hepatoid carcinoma Journal of Hepatology doi.org/10.1016/j.jhep… 👉autologous T-cell therapy targeting AFP 🧐Still early, but we are moving to🎯 & cell therapies in HCC ESMO - Eur. Oncology EASL Education ILCA